PUMA BIOTECHNOLOGY (PBYI) Stock: Buy, Sell, or Hold?
PBYI - PUMA BIOTECHNOLOGY INC
$9.12
-0.05 (-0.55%)
âŧ
5d:
-3.08%
30d:
+2.47%
90d:
+26.14%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PBYI is fairly priced but lacks strong directional signals. At 18.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PBYI is fairly priced but lacks strong directional signals. At 18.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.11
Based on -16.2% avg growth
INTRINSIC VALUE TODAY
$1.31
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $9.12, which is considered fair relative to its 30-day fair value range of $8.57 to $9.45. From a valuation perspective, the stock is trading at a premium (Forward PE: 26.1) compared to its historical average (15.7). At these levels, the market is pricing in 18.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $8.78, while resistance sits at $9.73.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $6.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $8.78, while resistance sits at $9.73.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $6.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.57 -
$9.45
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.2%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 34.2% above Wall St target ($6.00)
- NEUTRAL: Trading at premium valuation - market expects 18.3% growth which is achievable
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.57 -
$9.45
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.79
(8.7%)
Support & Resistance Levels
Support Level
$8.78
Resistance Level
$9.74
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
26.06
Wall Street Target
$6.00
(-34.2%)
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
35.8%
Profit Margin
11.6%
Valuation Premium vs History
+18.3% premium
PE vs Historical
26.1 vs 15.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+18.3%
(market-implied from PE analysis)
1-Year Target
$10.79
(+18%)
2-Year Target
$12.76
(+40%)
3-Year Target
$15.10
(+66%)
3-Yr Target (if PE normalizes)
(PE: 26â16)
PE COMPRESSION
$9.10
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 26.1, Growth: -36.4%)
$6.65
(+-27%)
Base:
(SPY PE: 20.2, Growth: -36.4%)
$5.15
(-44%)
Bear:
(PE: 15.7, Growth: -36.4%)
$4.01
(-56%)
đ
Valuation based on Current Earnings
Trailing PE: 17.63 | Current EPS (TTM): $0.52
Bull Case
$6.79
(-26%)
Analyst growth -32.7%, PE expands to 19.4
Base Case
$6.17
(-32%)
Market implied -32.7%, PE stable at 17.6
Bear Case
$6.24
(-32%)
Severe decline -20.0%, PE contracts to 15.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 11:10 PM ET
Data refreshes hourly during market hours. Next update: 12:10 AM
Data refreshes hourly during market hours. Next update: 12:10 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$135 | 47 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
